GOVERNOR'S ANNUAL REPORT 2022

MARYLAND COMMISSION ON KIDNEY DISEASE and TRANSPLANTATION

4201 PATTERSON AVENUE BALTIMORE, MD 21215 Phone number 410-764-4799 Website: https://health.maryland.gov/mdckd

Dr. Sumeska Thavarajah, Chairman

Dr. Sonal Korgaonkar, Vice-Chairman

Eva Schwartz, M.S., M.T. SBB (ASCP), Executive Director

Donna Adcock, RN, Health Facilities Surveyor

Leslie Schulman, Assistant Attorney General, Commission Counsel

MARYLAND COMMISSION ON KIDNEY DISEASE REPORT TO THE GOVERNOR

January 1, 2022 – December 31, 2022

"The Commission shall adopt physical and medical standards for the operation of dialysis and renal transplant centers..."

"The Commission shall adopt reasonable medical standards for acceptance of patients into the treatment phase of the Program..."

"The Commission shall annually evaluate the entire Kidney Disease Program. An annual report of such evaluation shall be made to the Governor..."

"The Commission shall survey periodically dialysis and transplant facilities..."

"The Commission shall evaluate patient complaints, including cases of verbally and physically abusive patients..."

"The Commission shall collect an annual certification fee from the facilities in order to meet its mandated responsibilities..."

Annotated Code of Maryland Health-General Article, Title 13, Subtitle 3 and Title 16, Subtitle 2

MEMBERSHIP

Sumeska Thavarajah, M.D. - Chairman Sonal Korgaonkar, M.D. -Vice Chairman Jeremy Yospin, M.D. Adam Berliner, M.D. Donna Hanes, M.D. Susan Leon, R.N. Nadiesda Costa, M.D. Raymond Harris Tisha Guthrie, LMSW Andrene Townsend, R.N. Jacqueline Hires, LCSW, NSW-C Jerome Chiat

STAFF

During the calendar year 2022, Eva H. Schwartz, M.S., M.T. (ASCP) SBB held the position of Executive Director of the Commission. Leslie Schulman served as the Assistant Attorney General assigned as Counsel to the Commission, and Donna Adcock, R.N. served as the Commission Surveyor of the dialysis and transplant centers. The website manager was Oladunni Akinpelu.

COMMISSION MEETINGS

The Commission met virtually in January 2022, April 2022, July 2022, and October 2022.

PHYSICAL AND MEDICAL STANDARDS COMMITTEE

The Physical and Medical Standards Committee reviews on-site inspections, and approves facilities requesting certification by the Commission on Kidney Disease for reimbursement purposes by the Kidney Disease Program of Maryland (KDP). The Committee is responsible for research, recommendation and presentation of physical and medical issues affecting the renal community and investigation of patient complaints in an expeditious manner. The recommendations for complaint resolution cases are then voted on by the full Commission and appropriate corrective action is implemented and enforced. If necessary, a facility will be resurveyed because of non-compliance with its own submitted Plan of Correction (POC).

During the 2022 calendar year, the following <u>new</u> facilities were approved for certification by the Commission for KDP reimbursement purposes:

<u>Facility</u>	Address	Medical Director
FMC – Waldorf West	3015 Technology Place, Ste. 120 Waldorf, MD 20601	Dr. Sanjeeb Mishra
Davita – Hyattsville	5803-A Eastern Avenue Chillum, MD 20782	Dr. Roopali Gupta

Additional responsibilities of the Commission are to conduct on-site surveys of the dialysis and transplant facilities throughout the State of Maryland. The Commission surveys the dialysis and transplant facilities to meet the regulatory standards as promulgated by the Commission. An annual certification fee collected by the Commission is an additional requirement of the facilities for certification with the Commission and eligibility for reimbursement from the KDP. Enclosed is the roster of all certified dialysis and transplant centers in Maryland. This informational roster is available upon request from the Commission, and is posted on the Commission's website: health.maryland.gov/mdckd.

COMMISSION ACCOMPLISHMENTS

- The Commission investigated and resolved complaints between patients and facilities. Additionally, the Commission surveyed seventy-one (71) facilities for compliance with standards of care, and addressed all corrective action plans that emerged from such surveys. Surveys are scheduled based on need related to compliance of the facilities and transplant centers with submitted corrective plans and in response to patient complaints.
- The Commission reserves the right to schedule surveys to administer and manage the program as statutorily mandated and according to budgetary allowances and available funds.

- The Commission maintains an active and up to date website (health.maryland.gov/mdckd) for the latest information in the renal field as well as references the Commission's activities and community education accomplishments.
- In calendar year 2022, the Commission surveyed seventy-one (71) dialysis facilities. Through the Corrective Action Plan process, all Federal and State regulations were enforced by the Commission, thus the Commission has met its mandate. By enforcing compliance with State, Federal and Commission regulations, the quality of care rendered to the End Stage Kidney Disease (ESKD) population in the state of Maryland was enhanced and its citizenry protected.
- The Commission continues to work with the Office of Healthcare Quality (OHCQ) to foster communication between the two offices. The collaborative relationship between the Commission and OHCQ enables both entities timely responses to complaints, and therefore patients' welfare and safety is addressed through immediate intervention.
- Commission representatives participated in the Quality Insights quarterly teleconferences.
 The teleconferences provide a forum for Network staff to foster communication with the Commission and the OHCQ, to discuss any facility issues and provide updates on Network projects.
- The Commission provides invaluable resources to the Renal Community and the State. The Commissioners offer a wealth of information and experience regarding the care of End Stage Renal Disease patients. The Commission is comprised of dedicated and talented volunteers.
- The Commission reports on legislative efforts that affect the renal community.
- The Commission completed and distributed a newsletter to the Renal Community. The
 newsletter is a tool to inform the community about the Commission's activities, and to
 provide educational information. Each published Newsletter is available on the
 Commission's website.
- Commission meetings are forums for Community Education. Commissioners present
 educational topics at each Commission meeting. This year's educational topics included:
 kidney transplant allocation, home renal fellowship programs, Xenotransplantation, the
 nursing shortage, bed bug recommendations for dialysis facilities, strategies for decreasing
 involuntary discharges, and ADA laws and reasonable accommodations.
- The Commission meetings are forums to inform and educate the Renal Community. Facilities are encouraged to participate in the meetings and present best practice scenarios. All Open Session minutes are posted on the Commission's website and available for review by the Renal Community, all dialysis facilities and their staff.
- The Commission addressed ongoing issues surrounding dialysis facilities' discharge practices and continuity of care issues. The Commission utilizes the Involuntary Discharge Packet and the process for handling and conducting investigations of complaints. The Commission works collaboratively with the Quality Insights network to review facility discharge requests.

- The Commission in collaboration with the Maryland Board of Nursing (MBON) continues to enforce the licensure requirement that only Certified Nursing Assistants with a DT (dialysis technician) specification are permitted to provide care for dialysis patients.
- The Commission supported HB 218. This bill repealed the requirement for a dialysis technician to be a Certified Nursing Assistant (CNA) and establishes a separate certification for a Certified Dialysis Technician (CDT). The Commission looks forward to working with the Maryland Board of Nursing's Advisory Committee to develop and recommend the new CDT regulations.
- The Commission continues to provide the KDP with expert medical advice.
- The Commission reviews out of state transplant center requests for KDP reimbursement as well as evaluates requests for inclusion of new medications in the KDP pharmaceutical formulary.
- Commission meetings provide a forum for Renal Community education regarding KDP policies and requirements.
- The Commission continues to work with local hospitals to assist with the placement of difficult patients in community dialysis facilities.
- The Commission communicates with the medical and management leadership of facilities that are cited with concerning deficiencies. The discussions serve as an educational tool and encourages enforcement of compliance with the Commission's COMAR.
- The Commission remains vigilant regarding nursing and staffing ratios in dialysis facilities. Facility representatives are educated on current staffing requirements; including the requirement of the facility's Governing Body to assure staffing in the facilities meet the needs of the patients. The Commission urges administrators, medical directors and governing bodies to routinely evaluate the staffing ratios to assure that facility staffing meets the needs of their patients so that compromises in health and safety may be avoided.
- The Commission reported on the Dialysis Community Response Needs Team. This team includes several leading dialysis providers who collaborate to provide adequate capacity for the temporary treatment of outpatient dialysis patients who are or are suspected to be COVID-19 positive.
- The Commission initiated a new electronic payment system for Commission certification and certification renewals.
- The Commission updates the renal community with National Kidney Foundation educational and fundraising opportunities.

PATIENT GRIEVANCES

During the year 2022, the Commission resolved to the satisfaction of the patients and the dialysis facilities more than forty (40) complaints. The Commission and staff have availed themselves to the renal community to expeditiously resolve problems arising between patients and facilities. Additionally, the Commission has mandated improvement in the quality of care provided at the facilities cited for deficiencies and violations during the ESKD Survey. These goals were accomplished to the satisfaction of the Commission, thus protecting the safety and welfare of this vulnerable patient population.

COMMUNITY EDUCATION

The Commission has fulfilled its community education responsibilities by surveying and educating facilities according to the promulgated regulations by the Commission on Kidney Disease, COMAR 10.30.01. The Commission, public member volunteers, and patient advocates have addressed numerous groups in the renal community regarding sources for reimbursement for renal care, prevention of renal disease, transplantation criteria, and methods for reimbursement for life saving medications.

STATUS OF THE KIDNEY DISEASE PROGRAM

The purpose of the Kidney Disease Program (KDP) is to provide financial assistance to certified beneficiaries for the treatment of ESRD (end stage renal disease). This stage of renal impairment is almost always irreversible and requires dialysis or kidney transplantation to maintain life. As a payer of last resort, the Program may provide financial assistance only after all other medical and federal insurance coverage has been pursued. Covered services include chronic maintenance, in-center and home dialysis, renal transplantation, approved inpatient and/or outpatient hospital care, physician and laboratory fees, and medications specified on the KDP Reimbursable Drug List and certain ancillary services which are directly attributable to the beneficiaries' ESRD.

PROGRAM STATISTICS

In Fiscal Year, 2022, the Kidney Disease Program provided coverage to approximately 1,492 beneficiaries. KDP net expenditures for FY 2022 totaled \$ 9,307,451. KDP recovered \$ 287,624 in premiums and \$ 233,747 in provider refunds. Drug Rebate recoveries totaled \$ 583,298 in FY 2022. These recoveries are projected annually and are incorporated into the Program's reimbursement budget.

FISCAL YEAR 2022 ACCOMPLISHMENTS

The Kidney Disease Program (KDP) enhanced the Program's website with information and updates relative to the Program. The address of this website is:

https://mmcp.health.maryland.gov/familyplanning/Pages/kidneydisease.aspx This website includes helpful information, such as: KDP notices of updates/changes, information resources, web links, phone numbers, e-mail address for questions about KDP, billing instructions, KDP COMAR regulations and the KDP drug formulary. This website will undergo continuing development in an effort to provide the renal community with the most up to date information available with regard to the Kidney Disease Program. The KDP Brochure has also been updated. The brochure may be viewed at https://mmcp.health.maryland.gov/familyplanning/Documents/KDP.pdf Enhancements and system developments to the KDP electronic claims management system (eCMS) and the Conduent pharmacy point-of-sale system (POS) continue in an effort to provide more efficient and timelier processing of claims. These systems continue to allow KDP to accept and return HIPAA compliant transactions from Medicare trading partners and all participating providers.

ESRD providers of service continue to be granted access to the KDP Portal. User agreements must be submitted online through the updated portal. Approval of user agreements has improved to a 48 hour or less processing window. To gain access to the current KDP Provider Portal, users must utilize their user name and password to log into www.mdeclaims.health.maryland.gov . The KDP portal allows providers to verify claims' status and view detailed payment information, which includes, check numbers, check dates and voucher numbers. This information assists providers in maintaining an accurate and up to date accounts receivable system and minimizes duplicate billing. In addition, providers of service may access up to date eligibility information for all ESRD patients certified with the Kidney Disease Program of MD.

The Kidney Disease Program is successfully transmitting a KDP recipient eligibility file, resource file and a COB Connect document to HMS (Health Management Services) on a monthly basis in an effort to gather patients' third-party insurance information to maximize collection efforts, update the KDP eligibility file with accurate TPL information and ensure that KDP is the payer of last resort. KDP is working with HMSunder a new contract, in an effort to continue maximizing the State's collection efforts and ensure cost effectiveness among all MDH programs.

KDP has transitioned to working with MDThink to implement a new workflow automation system using the Salesforce platform. This platform will include a Patient Enrollment and Case Management system, Recovery and Recoupment capabilities, Premium Management system, Online Provider and Patient Portals and additional functionalities. The scheduled go live date is May 16, 2023.

KDP, along with MD Medicaid, BCCDT and MADAP, has secured a new contract with Conduent for a pharmacy point-of-sale electronic claims management system (POSECMS). The new contract went into effect October 31, 2022. This enhanced system provides updates and adds compliance to the existing pharmacy point-of-sale claims processing system.

KDP, along with BCCDT and CMS, contracts with Santeon, the current KDP electronic claims processing (eCMS) vendor, to continue the KDP claims functioning processes, financial payments and recoveries, in addition to reporting requirements. This contract has been extended through FY 2023.

Customer service in the areas of patient certification, accounts payable and accounts receivable continues to improve. KDP personnel strive to assist KDP recipients, in processing applications as quickly and efficiently as possible, adjudicate claims in a timely manner, assist with explaining the calculation and billing of program participation fees, and provide guidance to members of the renal community to assist them in receiving the most accurate information possible. Training sessions have been held with Free Standing Dialysis Unit (FSDU) social workers and Senior Health Insurance Program (SHIP) personnel in an effort to educate the ESRD personnel and community in the KDP patient certification process, advise those personnel of KDP, Medicare and Medicaid regulations, and address frequent problems and concerns occurring with those processes.

PROJECTIONS FOR THE KIDNEY DISEASE PROGRAM

The Kidney Disease Program continues to work with our contractors, Santeon, HMS, Conduent and MDThink, in addition to data processing analysts and programmers, to ensure compliance with State and Federal mandated requirements. The Kidney Disease Program will strive to deliver the best services possible to ensure that each KDP recipient continues to receive quality medical care and efficient customer service from KDP staff.

KDP will continue to work with its colleagues in defining the best possible route to obtaining and developing a new KDP electronic claims processing system and completing the development of the Patient Enrollment, Case Management and PremiumManagement systems. In addition, the Kidney Disease Program will continue to work with the Commission on Kidney Disease to provide quality service and education to end stage renal disease (ESRD) patients in the State of Maryland and ESRD community.